Secretome Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Secretome Therapeutics - overview
Established
2018
Location
Baltimore, MD, US
Primary Industry
Pharmaceuticals
About
Secretome Therapeutics, based in the USA, develops innovative therapies from neonatal cardiac progenitor cells (nCPCs) to address unmet needs in cardiovascular disease treatment. Secretome Therapeutics focuses on creating therapies from neonatal cardiac progenitor cells, emphasizing treatments for heart failure and dilated cardiomyopathy. Founded in 2018 in Baltimore, US, the company has made three deals, with its latest funding round raising USD 20. 4 mn on November 25, 2024.
The founder's history is not publicly available. Secretome Therapeutics specializes in developing innovative therapies derived from neonatal cardiac progenitor cells (nCPCs) to address significant unmet medical needs in the treatment of cardiovascular diseases. Their lead products, STM-01 and its secretome, STM-21, target heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy (DCM). The therapies are aimed at healthcare professionals and clinical researchers, with ongoing clinical trials to enroll diverse patient demographics.
Secretome Therapeutics generates revenue primarily through the development and commercialization of investigational medicines via clinical trials and partnerships with healthcare organizations. Collaborations with clinical research institutions enable the assessment of product efficacy and safety. Specific pricing plans for their therapies have not been disclosed, but the company focuses on B2B relationships with research entities and healthcare providers, with potential revenue streams from successful trial outcomes leading to licensing agreements or partnerships for STM-01 and STM-21. In November 2024, Secretome Therapeutics raised USD 20.
4 mn in venture funding, which will be utilized to finance operations and initiate clinical research on STM-01, its main asset. The company plans to expand its reach into new markets, though specific regions have not been detailed. Upcoming product developments are focused on advancing current therapeutic offerings, with timelines dependent on trial outcomes.
Current Investors
HEST Investment
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.secretometherapeutics.com/
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.